TW201726914A - 可程式化的通用細胞受器及其使用方法 - Google Patents

可程式化的通用細胞受器及其使用方法 Download PDF

Info

Publication number
TW201726914A
TW201726914A TW105134363A TW105134363A TW201726914A TW 201726914 A TW201726914 A TW 201726914A TW 105134363 A TW105134363 A TW 105134363A TW 105134363 A TW105134363 A TW 105134363A TW 201726914 A TW201726914 A TW 201726914A
Authority
TW
Taiwan
Prior art keywords
cells
cell
catalytic
antibody
acid sequence
Prior art date
Application number
TW105134363A
Other languages
English (en)
Chinese (zh)
Inventor
古納 喬格 佛羅瑞思 考夫曼
燕文 傅
張延良
詹姆士 T 派特森
Original Assignee
索倫多醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 索倫多醫療公司 filed Critical 索倫多醫療公司
Publication of TW201726914A publication Critical patent/TW201726914A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/15Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4274Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276Prostate specific membrane antigen [PSMA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70517CD8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002Antibodies with enzymatic activity, e.g. abzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW105134363A 2015-10-23 2016-10-24 可程式化的通用細胞受器及其使用方法 TW201726914A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562245978P 2015-10-23 2015-10-23
US201662382691P 2016-09-01 2016-09-01

Publications (1)

Publication Number Publication Date
TW201726914A true TW201726914A (zh) 2017-08-01

Family

ID=58558187

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105134363A TW201726914A (zh) 2015-10-23 2016-10-24 可程式化的通用細胞受器及其使用方法

Country Status (11)

Country Link
US (1) US20170112878A1 (enExample)
EP (1) EP3365016A4 (enExample)
JP (1) JP2018537076A (enExample)
KR (1) KR20180091820A (enExample)
CN (1) CN108883170A (enExample)
AU (1) AU2016341321A1 (enExample)
CA (1) CA3002774A1 (enExample)
EA (1) EA201890941A1 (enExample)
TW (1) TW201726914A (enExample)
UY (1) UY36961A (enExample)
WO (1) WO2017070654A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016341321A1 (en) * 2015-10-23 2018-06-07 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2019010201A1 (en) * 2017-07-03 2019-01-10 Yale University REGULATED SMALL MOLECULE ADAPTER
KR20200076732A (ko) * 2017-11-03 2020-06-29 소렌토 쎄라퓨틱스, 인코포레이티드 Cd38-지시된 키메라 항원 수용체 작제물
WO2019173837A1 (en) * 2018-03-09 2019-09-12 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dar)
AU2020369479A1 (en) * 2019-10-23 2022-05-26 University Of Florida Research Foundation, Incorporated Novel conjugation chemistry for catalytic antibody 38C2
US20230096410A1 (en) * 2020-03-06 2023-03-30 Sorrento Therapeutics, Inc. Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells
EP4225799A4 (en) * 2020-10-12 2024-11-20 Sorrento Therapeutics, Inc. CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS
EP4274852A4 (en) * 2021-01-11 2025-02-26 Eutilex Co., Ltd. BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF
CA3215938A1 (en) * 2021-04-23 2022-10-27 Henry Hongjun Ji Dimeric antigen receptors (dars) that bind gd2
WO2023154708A2 (en) * 2022-02-10 2023-08-17 The Scripps Research Institute Car-t therapies targeted via covalently bonded adapters

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268488B1 (en) * 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
AU2004210088A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
CA2696627C (en) * 2007-08-17 2016-09-27 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2483301A1 (en) * 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
EP2593142B8 (en) * 2010-07-12 2018-12-26 Pfizer Healthcare Ireland Multifunctional antibody conjugates
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN107188969B (zh) * 2011-04-08 2021-08-27 美国卫生和人力服务部 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途
WO2013044225A1 (en) * 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
AU2016341321A1 (en) * 2015-10-23 2018-06-07 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same

Also Published As

Publication number Publication date
WO2017070654A8 (en) 2017-06-01
EP3365016A4 (en) 2019-07-17
KR20180091820A (ko) 2018-08-16
AU2016341321A1 (en) 2018-06-07
UY36961A (es) 2017-05-31
CA3002774A1 (en) 2017-04-27
WO2017070654A1 (en) 2017-04-27
EP3365016A1 (en) 2018-08-29
US20170112878A1 (en) 2017-04-27
JP2018537076A (ja) 2018-12-20
EA201890941A1 (ru) 2018-11-30
CN108883170A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
TW201726914A (zh) 可程式化的通用細胞受器及其使用方法
US20240374748A1 (en) Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
JP6734227B2 (ja) 抗cd276抗体(b7h3)
JP6632073B2 (ja) キメラ抗原受容体
JP7275118B2 (ja) 抗cd22免疫療法によってがんを処置するための組成物および方法
JP2023518049A (ja) 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
JP7035170B2 (ja) 抗cd19免疫療法によりがんを処置するための組成物および方法
JP2020533958A (ja) 抗cd19/cd20免疫療法によりがんを処置するための組成物および方法
JP2022502043A (ja) 抗cd19/cd22免疫療法によりがんを処置するための組成物および方法
IL292996A (en) Prame tcr receptors and uses thereof
JP2015513394A (ja) 二重特異性キメラ抗原受容体およびその治療的使用
JP2022524507A (ja) 自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法
JP2024507875A (ja) 制御された特異的car t細胞活性のためのキメラ抗原受容体(car)シグナル伝達分子
CN111315872A (zh) 用于癌症的过继性细胞疗法的组合物和方法
EP4261225A1 (en) Anti-pd-1 antibody and uses thereof
JP2023542230A (ja) Prame特異的t細胞受容体およびその使用
CN117412984A (zh) 通过使用近端信号传导分子增强t细胞功能
US20250353931A1 (en) Multi-specific reagent for targeted delivery of lipid nanoparticles
WO2025255266A1 (en) Engineered polypeptides for immune cell activation
WO2025158420A1 (en) Methods and composition for inducing activation and dna expression in t-cells
WO2025218621A1 (zh) 靶向muc1的抗原结合蛋白
TW202535941A (zh) 具有特製藥物對抗體比之抗體-藥物結合物
WO2025259362A1 (en) Enhancements for proximal signaling car activation
WO2024081824A2 (en) Synthetic intermediates for universal chimeric antigen receptor immune cell therapies
WO2023133424A2 (en) Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides